UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/ HR-, HER2+breast cancer

被引：0
|
作者：
McAndrew, Nicholas Patrick [1 ]
Hurvitz, Sara A. [1 ]
Tetef, Merry L. [1 ]
Kivork, Christine [1 ]
Ikenouye, Larissa [1 ]
Slamon, Dennis J. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1116
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    De Laurentiis, Michelino
    CANCER RESEARCH, 2020, 80 (04)
  • [42] MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
    Strickler, John H.
    Ng, Kimmie
    Cercek, Andrea
    Fountzilas, Christos
    Sanchez, Federico Augusto
    Hubbard, Joleen M.
    Wu, Christina
    Siena, Salvatore
    Tabernero, Josep
    Van Cutsem, Eric
    Kardosh, Adel
    Saeed, Anwaar
    Andre, Thierry
    Stecher, Michael
    Palanca-Wessels, Maria Corinna
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+breast cancer (TRIO-US B07)
    Hurvitz, S. A.
    Miller, J. M.
    Dichmann, R.
    Perez, A. T.
    Patel, R.
    Zehngebot, L. M.
    Allen, H.
    Bosserman, L. D.
    DiCarlo, B. A.
    Kennedy, A.
    Giuliano, A.
    Calfa, C. J.
    Molthrop, D. C.
    Mani, A.
    Dering, J.
    Wang, H-J
    Adams, B.
    Martinez, D.
    Chen, W.
    Zoeller, J.
    Brugge, J. S.
    Slamon, D. J.
    CANCER RESEARCH, 2013, 73
  • [44] A randomized, opened, phase II trial assessing the efficacy and safety of ATH-TH(doxorubicin/docetaxel/trastuzumab followed by docetaxel/trastuzumab) versus TCH(docetaxel/carboplatin/trastuzumab) as neoadjuvant treatment in HER2-positive breast cancer
    Wang, Tao
    Zhou, Jin-Mei
    Hao, Xiao-Peng
    Zhang, Hui-Qaing
    Zhang, Shao-Hua
    Bian, Li
    Jiang, Ze-Fei
    CANCER RESEARCH, 2021, 81 (04)
  • [45] MetaPHER: A phase IIlb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer
    Kummel, S.
    Crepelle-Flechais, A.
    Schlegel, M.
    Hillenbach, C.
    Swat, A.
    Franz, M.
    Girase, P.
    Schneider, A.
    Heinzmann, D.
    Shing, M.
    CANCER RESEARCH, 2016, 76
  • [46] Updated results of a randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC): efficacy and safety
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Cobleigh, Melody
    Albain, Kathy
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 39 - 39
  • [47] A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE)
    Patel, Rima
    Cascetta, Krystal
    Klein, Paula
    Moshier, Erin
    Kwa, Maryann
    Fasano, Julie
    Goel, Anupama
    Accordino, Melissa
    Shapiro, Charles
    Vaccaro, Rita
    Joshi, Gargi Atul
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [48] EFFICACY AND SAFETY OF TRASTUZUMAB-DM1 VERSUS TRASTUZUMAB PLUS DOCETAXEL IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS WITH NO PRIOR CHEMOTHERAPY FOR METASTATIC DISEASE: PRELIMINARY RESULTS OF A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE 2 STUDY (TDM4450G)
    Perez, E. A.
    Dirix, L.
    Kocsis, J.
    Gianni, L.
    Lu, J.
    Vinholes, J.
    Ng, V.
    Linehan, C.
    Agresta, S.
    Hurvitz, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 2 - 2
  • [49] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [50] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Ian E. Krop
    Shanu Modi
    Patricia M. LoRusso
    Mark Pegram
    Ellie Guardino
    Betsy Althaus
    Dan Lu
    Alexander Strasak
    Anthony Elias
    Breast Cancer Research, 18
12345